Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials.

Abstract

PURPOSE:

Erectile dysfunction is a common problem, particularly in diabetics. It is associated with a considerable burden of suffering. No generally accepted drug treatment exists. We systematically reviewed and meta-analyzed all randomized, placebo controlled trials of yohimbine monotherapy for erectile dysfunction to determine its therapeutic efficacy. Our secondary aim was to evaluate the safety of yohimbine.

MATERIALS AND METHODS:

We used computerized literature searches and standardized data extraction to rate methodological quality in a meta-analysis using computer statistical software.

RESULTS:

Seven trials fit the predefined inclusion criteria. Overall methodological quality of these studies was satisfactory. The meta-analysis demonstrated that yohimbine is superior to placebo in the treatment of erectile dysfunction (odds ratio 3.85, 95% confidence interval 6.67 to 2.22). Serious adverse reactions were infrequent and reversible.

CONCLUSIONS:

The benefit of yohimbine medication for erectile dysfunction seems to outweigh its risks. Therefore, yohimbine is believed to be a reasonable therapeutic option for erectile dysfunction that should be considered as initial pharmacological intervention.

• Authors: E Ernst, M H Pittler
• Journal: The Journal of urology (J Urol) Vol. 159 Issue 2 Pg. 433-6 (Feb 1998) ISSN: 0022-5347 [Print] United States
• PMID: 9649257 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)

Chemical References

• Adrenergic alpha-Antagonists
• Yohimbine

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Double-Blind Method
• Erectile Dysfunction (drug therapy)
• Humans
• Male
• Randomized Controlled Trials as Topic
• Yohimbine (therapeutic use)